- Home
- PSNY vs KNSA Comparison
PSNY vs KNSA Comparison
Compare PSNY & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNY
- KNSA
- Stock Information
- Founded
- PSNY 2017
- KNSA 2015
- Country
- PSNY Sweden
- KNSA United Kingdom
- Employees
- PSNY N/A
- KNSA N/A
- Industry
- PSNY Auto Manufacturing
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- PSNY Consumer Discretionary
- KNSA Health Care
- Exchange
- PSNY Nasdaq
- KNSA Nasdaq
- Market Cap
- PSNY 2.4B
- KNSA 2.1B
- IPO Year
- PSNY N/A
- KNSA 2018
- Fundamental
- Price
- PSNY $1.08
- KNSA $28.04
- Analyst Decision
- PSNY Hold
- KNSA Strong Buy
- Analyst Count
- PSNY 5
- KNSA 6
- Target Price
- PSNY $1.26
- KNSA $39.33
- AVG Volume (30 Days)
- PSNY 3.7M
- KNSA 1.1M
- Earning Date
- PSNY 08-28-2025
- KNSA 07-22-2025
- Dividend Yield
- PSNY N/A
- KNSA N/A
- EPS Growth
- PSNY N/A
- KNSA N/A
- EPS
- PSNY N/A
- KNSA N/A
- Revenue
- PSNY $2,034,261,000.00
- KNSA $481,166,000.00
- Revenue This Year
- PSNY $101.15
- KNSA $37.21
- Revenue Next Year
- PSNY $54.99
- KNSA $5.32
- P/E Ratio
- PSNY N/A
- KNSA N/A
- Revenue Growth
- PSNY N/A
- KNSA 59.45
- 52 Week Low
- PSNY $0.61
- KNSA $17.82
- 52 Week High
- PSNY $1.94
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- PSNY 48.97
- KNSA 51.09
- Support Level
- PSNY $1.07
- KNSA $27.06
- Resistance Level
- PSNY $1.22
- KNSA $29.25
- Average True Range (ATR)
- PSNY 0.07
- KNSA 0.97
- MACD
- PSNY 0.00
- KNSA -0.06
- Stochastic Oscillator
- PSNY 26.32
- KNSA 50.83
About PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.